Cargando…
Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
PURPOSE: Fruquintinib is an anti-vascular endothelial growth factor receptor (VEGFR) agent. The FRESCO trial demonstrated that patients with metastatic colorectal cancer (mCRC) refractory to standard therapies could benefit from fruquintinib with tolerable adverse events (AEs). However, the efficacy...
Autores principales: | Wang, Lei, Cao, Huijiao, Jiang, Chang, He, Wenzhuo, You, Yafei, Peng, Kunwei, Jin, Yanan, Xia, Liangping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691567/ https://www.ncbi.nlm.nih.gov/pubmed/33282739 http://dx.doi.org/10.3389/fonc.2020.587692 |
Ejemplares similares
-
Optimal Surgery Type and Adjuvant Therapy for T1N0M0 Lung Large Cell Neuroendocrine Carcinoma
por: Peng, Kunwei, et al.
Publicado: (2021) -
Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study
por: Yang, Lin, et al.
Publicado: (2018) -
Real-World Data: Fruquintinib in Treating Metastatic Colorectal
Cancer
por: Liu, Shuai, et al.
Publicado: (2022) -
The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021) -
Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer
por: Zhang, Ying, et al.
Publicado: (2019)